{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T15:35:15Z","timestamp":1791992115861,"version":"4.4.0"},"reference-count":15,"publisher":"The Journal of Rheumatology","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2018,8]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>Anti-TNF-\u03b1 agents have significantly changed the management of juvenile idiopathic arthritis (JIA). We evaluated the safety and efficacy of adalimumab (ADA) and infliximab (IFX) for the treatment of JIA-associated uveitis in patients treated for \u2265 2 years.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>Patients with JIA-associated uveitis treated with IFX and ADA were managed by a standardized protocol and data were entered in the ORCHIDEA registry. At baseline, all patients were refractory to standard immunosuppressive treatment or were corticosteroid-dependent. Data recorded every 3 months were uveitis course, number\/type of ocular flares and complications, drug-related adverse events (AE), and treatment switch or withdrawal. Data of patients treated for \u2265 2 years were analyzed by descriptive statistics.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>Up to December 2014, 154 patients with \u2265 24 months followup were included in the study. Fifty-nine patients were treated with IFX and 95 with ADA. Clinical remission, defined as the absence of flares for &gt; 6 months on treatment, was achieved in 69 patients (44.8%), with a better remission rate for ADA (60.0%) as compared to IFX (20.3%; p &lt; 0.001). A significant reduction of flares was observed in all patients without difference between the 2 treatment modalities. The number of new ocular complications decreased in both groups but was lower for ADA (p = 0.015). No serious AE were recorded; 16.4% of patients experienced 35 minor AE and the incidence rate was lower with ADA than with IFX.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>At the 2-year followup, ADA showed a better efficacy and safety profile than IFX for the treatment of refractory JIA-associated uveitis.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.171006","type":"journal-article","created":{"date-parts":[[2018,4,15]],"date-time":"2018-04-15T11:35:13Z","timestamp":1523792113000},"page":"1167-1172","source":"Crossref","is-referenced-by-count":68,"title":["Longterm Safety and Efficacy of Adalimumab and Infliximab for Uveitis Associated with Juvenile Idiopathic Arthritis"],"prefix":"10.3899","volume":"45","author":[{"given":"Vanessa","family":"Cecchin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Elisabetta","family":"Zannin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Pontikaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Miserocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria P.","family":"Paroli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Bracaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise Pires","family":"Marafon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Pastore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fulvio","family":"Parentin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Simonini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"De Libero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda","family":"Falcini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Petaccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Filocamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"De Marco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"La Torre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvana","family":"Guerriero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvana","family":"Martino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Comacchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Muratore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Martini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Vittadello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Zulian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2018,4,15]]},"reference":[{"key":"2018112909385363000_45.8.1167.1","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/nrrheum.2015.20","article-title":"Uveitis associated with juvenile idiopathic arthritis","volume":"11","author":"Sen","year":"2015","journal-title":"Nat Rev Rheumatol"},{"key":"2018112909385363000_45.8.1167.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.09.048"},{"key":"2018112909385363000_45.8.1167.3","first-page":"390","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J Rheumatol"},{"key":"2018112909385363000_45.8.1167.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2005.03.057"},{"key":"2018112909385363000_45.8.1167.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2013.05.005"},{"key":"2018112909385363000_45.8.1167.6","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120583"},{"key":"2018112909385363000_45.8.1167.7","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.2147\/OPTH.S23646","article-title":"Long-term efficacy of adalimumab in the treatment of uveitis associated with juvenile idiopathic arthritis","volume":"5","author":"Kotaniemi","year":"2011","journal-title":"Clin Ophthalmol"},{"key":"2018112909385363000_45.8.1167.8","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-013-2275-x"},{"key":"2018112909385363000_45.8.1167.9","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22214"},{"key":"2018112909385363000_45.8.1167.10","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20404"},{"key":"2018112909385363000_45.8.1167.11","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem356"},{"key":"2018112909385363000_45.8.1167.12","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJMoa1614160","article-title":"Adalimumab plus Methotrexate for uveitis in juvenile idiopathic arthritis","volume":"376","author":"Ramanan","year":"2017","journal-title":"N Engl J Med"},{"key":"2018112909385363000_45.8.1167.13","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken298"},{"key":"2018112909385363000_45.8.1167.14","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1002\/art.38741","article-title":"Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry","volume":"66","author":"Schmeling","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2018112909385363000_45.8.1167.15","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu457"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.171006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T19:27:54Z","timestamp":1543519674000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.171006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,15]]},"references-count":15,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2018,8,1]]},"published-print":{"date-parts":[[2018,8]]}},"alternative-id":["10.3899\/jrheum.171006"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.171006","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,15]]}}}